Vaccines’ widespread use in healthy populations, including children, pregnant women and the elderly, establishes high societal requirements for effectiveness and product safety. As a result, vaccines require post-approval studies and surveillance activities to further monitor adverse effects between products or batches in near real time, as demonstrated by the European Medicines Agency’s (EMA) recent influenza vaccine guidelines.

As an experienced and specialized strategic research, operational and technology partner, Quintiles offers a comprehensive evidence development solution to help guide the design and implementation of a high-quality program tailored specifically to meet your needs and satisfy the evolving requirements of regulators, payers, providers and patients.